Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma

Cancer

Volumn 79, Issue 3, 1997, Pages 433-440

  Vollmers, H Peter ^a   Dämmrich, Jobst ^a   Hensel, Frank ^a   Ribbert, Hanno ^a   Meyer Bahlburg, Almut ^a   Ufken Gaul, Tobias ^a   Korff, Marlene V ^a   Müller Hermelink, Hans Konrad ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

apoptosis; diffuse type stomach carcinoma; Fas APO 1 CD95; intestinal type stomach carcinoma; p53; SC 1

Indexed keywords

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CARCINOMA;

EID: 1842376942     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970201)79:3<433::AID-CNCR2>3.0.CO;2-J     Document Type: Article

References (46)

1. Kerr JFR, Wyllie AH, Currie AR. Apoptosis:a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
2. Wyllie AH, Kerr JFR, Currie AR. Cell death:the significance of apoptosis. Int Rev Cytol 1980;68:251-306.
3. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980;284:555-6.
4. Wyllie AH, Morris AL, Smith AL, Dunlop D. Chromatin cleavage in apoptosis:association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 1984;142:67-77.
5. Williams GT, Smith CA. Molecular regulation of apoptosis:genetic controls of cell death. Cell 1993;74:76-9.
6. Rouvier E, Luciani MF, Golstein P. Fas involvement in Ca2+-independent T-cell mediated cytoxicity. J Exp Med 1993; 177:195-202.
7. Suda T, Nagata S. Purification and characterisation of the Fas-ligand that induces apoptosis. J Exp Med 1994;179:873-9.
8. Suda S, Takahashi T, Goldstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a member of the tumor necrosis family. Cell 1993;75:1169-78.
9. Vollmers HP, O'Connor R, Müller J, Kirchner T, Müller-Hermeiink HK. SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells. Cancer Res 1989;49:2471-6.
10. Vollmers HP, Dämmrich J, Ribbert H, Wozniak E, Müller-Hermelink HK. Apoptosis of stomach carcinoma cells induced by a human monoclonal antibody. Cancer 1995; 76:550-8.
11. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989;169:1747-56.
12. Trauth BC, Klas C, Peters AMJ, Matzku S, Möller P, Falk W, et al. Monoclonal antibody mediated tumor regression by induction of apoptosis. Science 1989;245:301-5.
13. Watanabe-Fukunaga R, Brannan C, Itoh N, Yonehara S, Copeland NG, Jenkins NA, et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992;148:1274-9.
14. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima SI, Sameshima M, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-43.
15. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member or the tumor necrosis/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 1992;267:10709-15.
16. Owen-Schaub LB, Radinsky R, Kruzel E, Berra K, Yonehara S. Anti-Fas on nonhematopoietic tumors. Levels of Fas/APO 1 and bcl-2 are not predictive of biological responsiveness. Cancer Res 1994;54:1580-6.
17. Ogasawara JR, Watanabe-Fukunaga M, Adachi A, Matsuzawa T, Kasugai Y, Kitamura N, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806-9.
18. Correa P. A human model for gastric carcinogenesis. Cancer Res 1988;48:38-45.
19. Correa P. Clinical implications of recent developments in gastric cancer pathology and epidemiology. Semin Oncol 1985;12:2-10.
20. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. Acta Pathol Microbiol Scand 1965;64:331-49.
21. Heider KH, Dämmrich J, Skroch-Angel P, Müller-Hermelink HK, Vollmers HP, Herrlich PH, et al. Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res 1993;53:4197-203.
22. Dämmrich J, Vollmers HP, Heider KH, Müller-Hermelink HK. Importance of different CD44v6 expression in human gastric intestinal and diffuse type cancers for metastatic lymphogenic spreading. J Mol Med 1995;73:395-401.
23. Sipponen P, Kekki M, Siurala M. Atrophic chronic gastritis and intestinal metaplasia in gastric carcinoma. Cancer 1983;52:1062-8.
24. Piper DW. Stomach cancer. In:Union Internationale Contre le Cancer, Technical Report Series 1978. Volume 34. Geneva: International Union Against Cancer, 1978.
25. Parsonnet J, Friedman G, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325:1127-31.
26. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez I, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991;325:1132-6.
27. Forman D, Newel NG, Fullerton F, Yarnell JWG, Stacey AR, Wald N, et al. Association between infection with Helicobacter pylori and risk of gastric cancer:evidence from a prospective investigation. B M J 1991;302:1302-5.
28. Vollmers HP, Dämmrich J, Ribbert H, Grassel S, Debus S, Heesemann J, et al. Human monoclonal antibodies from stomach carcinoma patients react with Helicobacter pylori and stimulate stomach cancer cells in vitro. Cancer 1994; 74:1525-32.
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival:application to proliferation and cytotoxic assays. J Immunol Methods 1983;65:55-63.
30. Carmichael J, DeGraff WD, Gazdar A, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay:assessment of chemosensitivity testing. Cancer Res 1987;47:936-42.
31. Vollmers HP, Stulle K, Dämmrich J, Pfaff M, Papadopoulos T, Betz C, et al. Characterization of four new gastric cancer cell lines. Virchows Archiv B 1993;63:335-43.
32. Laemmli UK. Cleavage of structural proteins during assembly of the head of bacteriophages T4. Nature 1970;227:680-5.
33. Pfaff M, O'Connor R, Vollmers HP, Müller-Hermelink HK. Human monoclonal antibody against a tissue polypeptide antigen-related protein from a patient with a signet-ring cell carcinoma of the stomach. Cancer Res 1991;50:5192-8.
34. Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993;69:415-29.
35. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994;78:703-11.
36. Hockenberry DM, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
37. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
38. Lauwers GY, Scott GV, Hendricks J. Immunohistochemical evidence of aberrant Bcl-2 protein expression in gastric epithelial dysplasia. Cancer 1994;73:2900-4.
39. Chiou S, Rao L, White E. Bcl-2 blocks p53 dependent apoptosis. Mol Cell Biol 1994;14:2556-63.
40. Li CJ, Wang C, Pardee AB. Induction of apoptosis by β-lapachanone in human prostate cancer cells. Cancer Res 1995;55:3712-5.
41. Fukunaga M, Monden T, Nakashini H, Ohue M, Fukuda K, Tomita N, et al. Immunohistochemical study of p53 in gastric cancer. Am J Clin Pathol 1994;101:177-80.
42. Joypaul BV, Hopwood D, Newman EL, Qureshi S, Grant A, Ogston SA, et al. The prognostic significance of accumulation of p53 tumour-suppressor gene in gastric adenocarcinoma. Br J Cancer 1994;69:943-6.
43. Klein RF, Vollmers HP, Müller-Hermelink HK. Different expression of bcl-2 in diffuse and intestinal-type stomach carcinomas. Oncol Rep 1996;3:1-4.
44. Yoshino T, Kondo E, Cao L, Takahashi K, Hayashi K, Nomura S, et al. Inverse expression of bcl-2 protein and Fas antigen in Iymphoblasts in peripheral lymph nodes and activated peripheral blood T and B lymphocytes. Blood 1994;83:1856-61.
45. Wright PA, Quirke P, Attanoos R, Williams GT. Molecular pathology of gastric carcinoma:progress and prospects. Hum Pathol 1992;23:848-59.
46. Tahara E. Molecular mechanism of stomach carcinogenesis. J Cancer Res Clin Oncol 1993;119:265-72.